liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients
University of Tokyo, Japan .
University of Tokyo, Japan .
University of Tokyo, Japan .
University of Tokyo, Japan .
Visa övriga samt affilieringar
2013 (Engelska)Ingår i: Circulation Journal, ISSN 1346-9843, E-ISSN 1347-4820, Vol. 77, nr 5, s. 1208-1213Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

BACKGROUND:

Urine osmolality (U-OSM) is valuable to predict response to tolvaptan (TLV) in decompensated heart failure patients, but measurement of U-OSM is not always available on site.

METHODS AND RESULTS:

Data were collected from 66 hospitalized patients with decompensated heart failure who had received TLV at 3.75-15 mg/day. U-OSM, which was estimated using the following formula: 1.07×{2×[(urine sodium (mEq/L)]+[urine urea nitrogen (mg/dl)]/2.8+[urine creatinine (mg/dl)]×2/3}+16, was well correlated with the actual measurement (r=0.938, P<0.001). Criteria consisting of C1 (estimated baseline U-OSM>358 mOsm/L) and C2 (%decrease in estimated U-OSM>24% at 4-6 h after the first TLV dose) significantly discriminated responders from non-responders (P<0.05).

CONCLUSIONS:

Response to TLV can be predicted using U-OSM, which can be estimated using urine urea nitrogen, sodium, and creatinine concentration data. 

Ort, förlag, år, upplaga, sidor
Japanese Circulation Society , 2013. Vol. 77, nr 5, s. 1208-1213
Nyckelord [en]
Hyponatremia; Responder; Vasopressin
Nationell ämneskategori
Hälsovetenskaper
Identifikatorer
URN: urn:nbn:se:liu:diva-111184DOI: 10.1253/circj.CJ-12-1328ISI: 000318320000020PubMedID: 23318562OAI: oai:DiVA.org:liu-111184DiVA, id: diva2:754522
Anmärkning

Funding Agencies|Japan Society for the Promotion of Science [224943]; Japanese Heart Foundation; Japanese Association for Cerebro-Cardiovascular Disease Control; AstraZeneca; Pfizer Health Research Foundation

Tillgänglig från: 2014-10-10 Skapad: 2014-10-10 Senast uppdaterad: 2020-01-13Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Person

Kato, Naoko

Sök vidare i DiVA

Av författaren/redaktören
Kato, Naoko
I samma tidskrift
Circulation Journal
Hälsovetenskaper

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 92 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf